ASCO 2016: Melanoma 3-year survival is robust after pembrolizumab treatment
by Bruce Sylvester: A follow-up evaluation of subjects from the phase 1b trial (KEYNOTE-001) of newly diagnosed and previously treated patients with advanced melanoma revealed a 40% survival… read more.